Inverna Therapeutics will be speaking to potential investors and collaboration partners at BioFIT on December 10th & 11th 2026
Inverna Therapeutics will attend BioFIT 2026 in Marseille. CEO Poul Sørensen speaks on alternative financing through patient association partnerships.
Meet up with Inverna Therapeutics at the TIDES Europe 2026 in Amsterdam, November 2026
Meet Inverna Therapeutics at TIDES Europe 2026, November 3–5 in Amsterdam — Europe’s leading event for oligonucleotides, peptides, mRNA and drug delivery.
Inverna Therapeutics will be presenting its innovation and scientific progress at the NLSDays – the premier Nordic Life Science Event in October 2026
Inverna Therapeutics will present its portfolio and scientific progress at NLSDays, October 8–9, 2026 in Stockholm. Meet our CEO for partnering opportunities.
Inverna Therapeutics attending the 26th Annual Biotech in Europe Forum (BEF), held October 7–8, 2026 in Basel
Inverna Therapeutics is taking part in the 26th Biotech in Europe Forum, on 7–8 October 2026 in Basel, to present its RNA therapy platform.
Inverna Therapeutics will participate in Oligonucleotides for CNS Summit Europe 2026
Inverna Therapeutics is pleased to announce its participation in the Oligonucleotides for CNS Summit Europe 2026, held April 21 – 23, 2026 in Amsterdam, Netherlands.
Connect with Inverna Therapeutics at BIO-Europe Spring 2026 and LSX World Congress Europe 2026
Inverna Therapeutics is pleased to announce its participation in the Life Science Spring Innovation Week 2026, featuring BIO-Europe Spring 2026, held March 23 – 25, 2026, and the directly following LSX World Congress Europe 2026, March 25 – 26, 2026.
Inverna Therapeutics to Showcase Breakthrough Pseudo-Exon Activation Platform at RNA Leaders Europe Congress
Inverna Therapeutics is pleased to announce that Chief Executive Officer, Poul Sørensen, has been invited to present at the RNA Leaders Europe 2026 Congress, taking place from March 17 to 19, 2026, at the Austria Center in Vienna.
Inverna Therapeutics will be presenting at BioCapital 2026
Inverna Therapeutics is pleased to announce that CEO Poul Sørensen will be presenting at the upcoming BioCapital 2026 conference organized by EQT Life Sciences.
Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.
Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.










